Featured at one of the most important global oncology meetings, attended by more than 44,000 oncology professionals from around the world, the poster details the background and methods of this pragmatic phase III trial.
DE-ESCALATE explores whether patients with metastatic hormone-sensitive prostate cancer whose PSA falls to very low levels after 6–12 months of maximum androgen blockade may safely interrupt treatment — aiming to improve quality of life and reduce treatment burden while preserving overall survival.
Read the poster here: https://deescalate-horizon.eu/publications/
© The DE-ESCALATE Consortium 2023-2028. This project has received funding from the European Union’s HORIZON-MISS-CANCER-2022-01 under grant agreement Nº (101104574 ). Views and opinions expressed are however those of the authors only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them.
Copyright © 2025 All rights reserved.
